461 related articles for article (PubMed ID: 24298069)
1. Metastasis dormancy in estrogen receptor-positive breast cancer.
Zhang XH; Giuliano M; Trivedi MV; Schiff R; Osborne CK
Clin Cancer Res; 2013 Dec; 19(23):6389-97. PubMed ID: 24298069
[TBL] [Abstract][Full Text] [Related]
2. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells.
Ogba N; Manning NG; Bliesner BS; Ambler SK; Haughian JM; Pinto MP; Jedlicka P; Joensuu K; Heikkilä P; Horwitz KB
Breast Cancer Res; 2014 Dec; 16(6):489. PubMed ID: 25475897
[TBL] [Abstract][Full Text] [Related]
3. Angiopoietin-2 promotes ER+ breast cancer cell survival in bone marrow niche.
Han HH; Kim BG; Lee JH; Kang S; Kim JE; Cho NH
Endocr Relat Cancer; 2016 Aug; 23(8):609-23. PubMed ID: 27353038
[TBL] [Abstract][Full Text] [Related]
4. New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target?
Goss P; Allan AL; Rodenhiser DI; Foster PJ; Chambers AF
APMIS; 2008; 116(7-8):552-68. PubMed ID: 18834402
[TBL] [Abstract][Full Text] [Related]
5. Reawakening of dormant estrogen-dependent human breast cancer cells by bone marrow stroma secretory senescence.
Tivari S; Lu H; Dasgupta T; De Lorenzo MS; Wieder R
Cell Commun Signal; 2018 Aug; 16(1):48. PubMed ID: 30119678
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals.
Huang J; Woods P; Normolle D; Goff JP; Benos PV; Stehle CJ; Steinman RA
Breast Cancer Res Treat; 2017 Jan; 161(2):229-243. PubMed ID: 27853906
[TBL] [Abstract][Full Text] [Related]
7. Understanding ER+ Breast Cancer Dormancy Using Bioinspired Synthetic Matrices for Long-Term 3D Culture and Insights into Late Recurrence.
Ovadia EM; Pradhan L; Sawicki LA; Cowart JE; Huber RE; Polson SW; Chen C; van Golen KL; Ross KE; Wu CH; Kloxin AM
Adv Biosyst; 2020 Sep; 4(9):e2000119. PubMed ID: 32603024
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding NR2F1-AS1 is associated with tumor recurrence in estrogen receptor-positive breast cancers.
Sanchez Calle A; Yamamoto T; Kawamura Y; Hironaka-Mitsuhashi A; Ono M; Tsuda H; Shimomura A; Tamura K; Takeshita F; Ochiya T; Yamamoto Y
Mol Oncol; 2020 Sep; 14(9):2271-2287. PubMed ID: 32392629
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer.
Gomez-Fernandez C; Daneshbod Y; Nassiri M; Milikowski C; Alvarez C; Nadji M
Am J Clin Pathol; 2008 Dec; 130(6):879-82. PubMed ID: 19019763
[TBL] [Abstract][Full Text] [Related]
10. Exploiting Mouse Models to Recapitulate Clinical Tumor Dormancy and Recurrence in Breast Cancer.
Gu Y; Bui T; Muller WJ
Endocrinology; 2022 Jun; 163(6):. PubMed ID: 35560214
[TBL] [Abstract][Full Text] [Related]
11. Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer.
Kim RS; Avivar-Valderas A; Estrada Y; Bragado P; Sosa MS; Aguirre-Ghiso JA; Segall JE
PLoS One; 2012; 7(4):e35569. PubMed ID: 22530051
[TBL] [Abstract][Full Text] [Related]
12. An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation.
Tivari S; Korah R; Lindy M; Wieder R
J Vis Exp; 2015 Jun; (100):e52672. PubMed ID: 26168083
[TBL] [Abstract][Full Text] [Related]
13. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms governing metastatic dormancy in breast cancer.
Dittmer J
Semin Cancer Biol; 2017 Jun; 44():72-82. PubMed ID: 28344165
[TBL] [Abstract][Full Text] [Related]
15. Disseminated Tumor Cells and Dormancy in Breast Cancer Progression.
Banys-Paluchowski M; Reinhardt F; Fehm T
Adv Exp Med Biol; 2020; 1220():35-43. PubMed ID: 32304078
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
[TBL] [Abstract][Full Text] [Related]
17. The ELEANOR noncoding RNA expression contributes to cancer dormancy and predicts late recurrence of estrogen receptor-positive breast cancer.
Fukuoka M; Ichikawa Y; Osako T; Fujita T; Baba S; Takeuchi K; Tsunoda N; Ebata T; Ueno T; Ohno S; Saitoh N
Cancer Sci; 2022 Jul; 113(7):2336-2351. PubMed ID: 35415910
[TBL] [Abstract][Full Text] [Related]
18. Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities.
Ramamoorthi G; Kodumudi K; Gallen C; Zachariah NN; Basu A; Albert G; Beyer A; Snyder C; Wiener D; Costa RLB; Czerniecki BJ
Semin Cancer Biol; 2022 Jan; 78():78-89. PubMed ID: 33626407
[TBL] [Abstract][Full Text] [Related]
19. Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence.
Aouad P; Zhang Y; De Martino F; Stibolt C; Ali S; Ambrosini G; Mani SA; Maggs K; Quinn HM; Sflomos G; Brisken C
Nat Commun; 2022 Aug; 13(1):4975. PubMed ID: 36008376
[TBL] [Abstract][Full Text] [Related]
20. [Clinical outcome of receptor expression discordance between primary and metastatic breast cancer].
Mu YX; Zhang P; Ma F; Yuan P; Wang JY; Xu BH; Li Q
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):506-511. PubMed ID: 30060358
[No Abstract] [Full Text] [Related]
[Next] [New Search]
